Episode 201: Radiopharmaceutical Therapy & Theranostics: A New Frontier in Thyroid and Cancer Care

Join Dr. Eric Balcavage as he explores the cutting-edge world of nuclear medicine with Dr. Munir Ghesani, Chief Medical Officer at United Theranostics. Discover how theranostics—the fusion of diagnostics and therapeutics—is revolutionizing cancer treatment, particularly for thyroid conditions. Key Topics Covered:

• The fascinating history of nuclear medicine, born from thyroid treatment in the 1940s
• How radioactive iodine therapy works and why it's so effective for thyroid cancer
• The difference between traditional treatment and modern theranostic approaches
• Revolutionary redifferentiation therapy that can restore cancer cells' ability to absorb iodine
• Applications beyond thyroid: prostate cancer and neuroendocrine tumors
• The role of AI in precision dosing and treatment planning
• Why hypothyroidism might be a protective response, not just a deficiency

What You'll Learn:

• When radioactive iodine treatment is recommended vs. traditional surgery
• How theranostics provides targeted treatment with fewer side effects
• The importance of proper patient selection and staging
• Future developments in nuclear medicine and personalized cancer care

Whether you're dealing with thyroid cancer, supporting someone who is, or simply interested in the latest advances in precision medicine, this episode offers invaluable insights into treatments that are changing lives.   https://unitedtheranostics.com/   Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI, is Chief Medical Officer at United Theranostics with 30+ years in nuclear medicine, specializing in theranostics, oncologic imaging, and targeted radiopharmaceutical therapies